Castelli Barbara, Fonte Carla, Guidi Milena, Tellini Marco, Di Nicola Marco, Iacono Alessandro, Buccoliero Anna Maria, Greto Daniela, Genitori Lorenzo, Sardi Iacopo
Health Sciences Department, University of Florence, Florence, Italy.
Neuro-Oncology Unit, Meyer Children's Hospital Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Florence, Italy.
Front Oncol. 2023 Sep 20;13:1244628. doi: 10.3389/fonc.2023.1244628. eCollection 2023.
Low grade gliomas (LGGs) of pineal region are usually difficult to remove and they frequently relapse or progress after front line chemotherapy. Bevacizumab-Irinotecan (BEVIRI) combination has been successfully attempted in children with recurrent LGGs, in most cases not previously irradiated. The efficacy of bevacizumab has also been described in radiation necrosis. Considering the possible overlapping of radiation treatment effect and disease progression and difficulty in differentiating, we report on the use of BEVIRI in a case of a recurrent relapsing low-grade glioma of the pineal region, subjected to multiple neurosurgical interventions, also treated with a carboplatin-etoposide regimen and a radiation course, at present at one-year follow-up showing a stable response, with no adverse events.
松果体区的低级别胶质瘤（LGGs）通常难以切除，并且在一线化疗后经常复发或进展。贝伐单抗-伊立替康（BEVIRI）联合方案已在复发性LGGs儿童中成功尝试，大多数病例此前未接受过放疗。贝伐单抗在放射性坏死中的疗效也有报道。考虑到放射治疗效果与疾病进展可能重叠且难以鉴别，我们报告了BEVIRI在一例复发性松果体区低级别胶质瘤中的应用，该病例接受了多次神经外科手术干预，也接受了卡铂-依托泊苷方案和一个疗程的放疗，目前随访一年显示反应稳定，无不良事件。
